Previous 10 | Next 10 |
SIFCO (NYSEMKT: SIF ) +61% on Q2 results . More news on: SIFCO Industries, Inc., United Natural Foods, Inc., Cyclacel Pharmaceuticals, Inc., Stocks on the move, , Read more ...
Gainers: CymaBay Therapeutics (NASDAQ: CBAY ) +134% . More news on: CymaBay Therapeutics, Inc., Novavax, Inc., Babcock & Wilcox Enterprises, Inc., Stocks on the move, , Read more ...
Gamida Cell (NASDAQ: GMDA ) is up 86% premarket after announcing positive topline results from its Phase 3 study evaluating the safety and efficacy of omidubicel, an investigational advanced cell therapy as a potential life-saving treatment option for patients in need of b...
— Study met primary endpoint of time to neutrophil engraftment — — Omidubicel represents potential transformative treatment option for patients in need of a bone marrow transplant — — Company anticipates initiating BLA submission in fourth quart...
Gamida Cell Ltd. (GMDA) Q4 2019 Results Earnings Conference Call February 25, 2020, 08:30 AM ET Company Participants Jaren Madden - Vice President, Investor Relations and Corporate Communications Julian Adams - CEO Ronit Simantov - Chief Medical Officer Shai Lankry - CFO Thom...
Gamida Cell (NASDAQ: GMDA ): FY GAAP EPS of -$1.69 misses by $0.62 . More news on: Gamida Cell Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
– Completed patient enrollment in Phase 3 clinical study of omidubicel; Topline data expected in the second quarter of 2020 – – Company to host conference call at 8:30 a.m. ET today – Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company com...
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on Tuesday, February 25, 2020, at 8:30 a.m. ET to review its full year 2019 fi...
– Topline data from Phase 3 study of omidubicel expected in first half of 2020 – – GDA-201 program progressing with additional data expected in first half of 2020 – – Jas Uppal, Ph.D., appointed as chief regulatory and quality officer – ...
– Topline data expected in first half of 2020 – Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, announced that in December the company completed patient enrollment in its Phase 3 ...
News, Short Squeeze, Breakout and More Instantly...
Gamida Cell Ltd. Company Name:
GMDA Stock Symbol:
NASDAQ Market:
CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney d...
2024-04-03 06:21:00 ET How to Analyze Different Penny Stocks Sectors to Make Money Investing in penny stocks offers an accessible entry point for individuals aiming to participate in the stock market with a lower initial investment. Analyzing different sectors within the realm of penn...
A look at the top 10 most actives in the United States Trio Petroleum Corp. (TPET) rose 43.8% to $0.1485 on volume of 202,621,744 shares Nikola Corporation (NKLA) fell 5.5% to $0.9736 on volume of 187,304,976 shares C3is Inc. (CISS) rose 13.3% to $0.0409 on volume of 136,767,990 shares ...